Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $79.05 | Total: $395.25 |
| 1 | 10 | $66.96 | Total: $669.60 |
| 1 | 25 | $56.73 | Total: $1,418.25 |
| 1 | 50 | $48.36 | Total: $2,418.00 |
| 1 | 100 | $41.85 | Total: $4,185.00 |
Overview
NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.NX-2127 potently catalyzes the degradation of Ikaros (IKZF1) and Aiolos (IKZF3) at 25 nM and 54 nM, respectively. NX-2127 is associated with the immune system, stimulating T cell activation and increasing IL-2 production in primary human T cells.
Chemical Properties
| Molecular Formula | C39H45N9O5 |
| Molecular Weight | 719.83 |
| CAS Numbers | 2416131-46-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C1C=2C(C(=O)N1C3C(=O)NC(=O)CC3)=CC=C(C2)N4C[C@H](CN5CCC(CC5)C6=CC=C(NC=7C(C(N)=O)=NC=C(N7)N8CCCCC8)C=C6)CC4 |
Storage and Handling
0C Short Term, -20C Long Term
References
Robbins D W, et al. Nx-2127, a degrader of BTK and IMiD neosubstrates, for the treatment of B-cell malignancies. Blood, 2020, 136 34.